Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 10/20 | 0.40 |
| ▸ | BTK | Q06187 | 7/20 | 0.38 |
| ▸ | ITK | Q08881 | 7/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19645647 | 0.83 | MET (0.39) | METMAP3K12BTKITKPRMT5 | |
| SCHEMBL13976070 | 0.82 | PRMT5 (0.43) | MAP3K12ITKPRMT5WDR77AXL | |
| SCHEMBL84406 | 0.81 | AXL (0.43) | ITKPRMT5WDR77AXL | |
| SCHEMBL84420 | 0.81 | MAP3K12 (0.41) | MAP3K12BTKITKPRMT5WDR77 | |
| SCHEMBL19105605 | 0.81 | MAP3K12 (0.41) | MAP3K12BTKPRMT5WDR77AXL | |
| SCHEMBL18352451 | 0.78 | MAP3K12 (0.35) | MAP3K12AXL | |
| SCHEMBL7921128 | 0.77 | MET (0.46) | METMAP3K12BTKITKPRMT5 | |
| SCHEMBL24012829 | 0.77 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL13523638 | 0.77 | MAP3K12 (0.47) | MAP3K12PRMT5WDR77 | |
| SCHEMBL19754768 | 0.77 | LRRK2 (0.47) | MAP3K12PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-10966987-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10758539-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200054644-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-10398703-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190216812-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2019-07-18 | — | — | US | disclosed |
| US-10285991-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-9096586-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10285991-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | MET 1975/4885MAP3K12 4043/4885BTK 3240/4885 |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MET 3530/4885MAP3K12 3112/4885BTK 1148/4885 |
| US-10758539-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | MET 1975/4885MAP3K12 4043/4885BTK 3240/4885 |
| US-10966987-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | MET 1954/4885MAP3K12 3983/4885BTK 2794/4885 |
| US-20130281434-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | MET 2336/4885MAP3K12 1699/4885BTK 4215/4885 |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | MET 1954/4885MAP3K12 3983/4885BTK 2794/4885 |
| US-20200054644-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | MET 1954/4885MAP3K12 3983/4885BTK 2794/4885 |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | MET 1954/4885MAP3K12 3983/4885BTK 2794/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MET 3530/4885MAP3K12 3112/4885BTK 1148/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MET 3530/4885MAP3K12 3112/4885BTK 1148/4885 |
| US-20190216812-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | MET 1975/4885MAP3K12 4043/4885BTK 3240/4885 |
| US-20160152582-A1 | THERAPEUTIC COMPOUNDS | NFATC1, FURIN, CD4 | MET 2336/4885MAP3K12 1699/4885BTK 4215/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MET 384/4885MAP3K12 91/4885BTK 169/4885 |
| US-10398703-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | MET 1954/4885MAP3K12 3983/4885BTK 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.